Auxilium Pharmaceuticals — Merger or Acquisition (October 2014)
16 slides from Auxilium Pharmaceuticals's merger presentation, Oct 9, 2014
Slide 1: Endo and Auxilium: A Compelling Business Combination
Endo and Auxilium: October 9, 2014 A Compelling Business Combination
Slide 2: Additional Information
ADDITIONAL INFORMATION This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to a proposed business combination transaction between Endo International plc ("Endo") and Auxilium Pharmaceuticals, Inc. ("Auxilium"). In furt
Slide 3: Forward-Looking Statements
This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. These forward-looking statements include, but are not limited to, statements regarding the proposed transaction, the financing of
Slide 4: Transaction Summary
4 Transaction Summary Endo to acquire Auxilium Pharmaceuticals for $33.25 per share in cash and stock Represents a 55% premium to Auxilium’s closing price on September 16, 2014 Implies transaction value of approximately $2.6 billion, including the assumption of debt Unanimously approved by both comp
Slide 5: Compelling Strategic and Financial Rationale
Expected to significantly enhances Endo's branded pharmaceutical business with the addition of Auxilium's leading men's health products and development portfolio Designed to accelerates growth and maximizes value of Auxilium’s products by leveraging strengths of combined company Enhance the long-ter
Slide 6: Transaction At a Glance
6 Transaction At a Glance Purchase Price: Premium: Synergies: Financing: $33.25 per share $2.6 billion total consideration, including the assumption of debt 55% to Auxilium’s closing stock price on September 16, 2014, the day Endo made public its proposal for Auxilium ~$175 million of identified ann
Slide 7: Auxilium Snapshot
7 Auxilium Snapshot Specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences Leader in men’s healthcare and has strategically expanded its product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas Bro
Slide 8: Combination Aligns with Endo's Strategic Direction
8 Endo executing strategic plan to enhance shareholder value Meeting or exceeding financial targets Maximizing the growth potential of core businesses Continued investment in de-risked R&D Lean and efficient operating model Pursuing accretive value creating M&A that delivers compelling financial ret
Slide 9: Demonstrated Record of Value Enhancing Transactions
9 Paladin Labs for cash and stock in November 2013 Expanded global footprint into Canada and emerging markets Established Irish domicile for advantaged corporate platform Boca Pharmacal in August 2013 and DAVA Pharmaceuticals in June 2014 Added significant near-term EBITDA and cash flow from operati
Slide 10: Accelerating Organic Growth
Auxilium’s FDA-approved products in urology, orthopedics, and other areas are natural complements to men’s health and pain products in Endo’s branded pharmaceuticals portfolio Endo expects to optimize Auxilium’s portfolio of products by leveraging scale, competencies and resources Drive increased ad
Slide 11: Select Highlights of Complementary Product Portfolio
Select Highlights of Complementary Product Portfolio Men’s Health / Urology Orthopedics / Pain Other Specialty 11 Testosterone Gel 1% Authorized Generic
Slide 12: Enhanced Pro Forma Financial Profile
12 Enhanced near- and long-term revenue growth profile Strong margin profile Immediate and meaningful long-term accretion Robust financial returns that are well in excess of combined cost of capital Enhanced cash flows provide balance sheet flexibility and rapid de-levering Deal structure enables co
Slide 13: Significant and Achievable Synergy Opportunities
13 Annual run-rate operating cost synergy estimated to reach approximately $175 million within the first 12 months after closing Leverage platform for more efficient operations, including cost savings in: Sales and Marketing R&D G&A Driven by complementary nature of companies’ product portfolios Syn
Slide 14: Roadmap to Completion
Combination of existing cash on hand and committed debt financing from Citi to fund the cash portion of the transaction Transaction is subject to: Regulatory approval in the U.S. and certain other jurisdictions Other customary closing conditions Expected to close in the first half of 2015 14 Roadmap
Slide 15: Compelling Strategic and Financial Rationale
Expected to significantly enhances Endo's branded pharmaceutical business with the addition of Auxilium's leading men's health products and development portfolio Designed to accelerate growth and maximizes value of Auxilium’s products by leveraging strengths of combined company Enhance the long term
Slide 16: Endo and Auxilium: A Compelling Business Combination
Endo and Auxilium: October 9, 2014 A Compelling Business Combination
Auxilium Pharmaceuticals — Merger or Acquisition (October 2014) on 6ix